Zetagen Therapeutics, a Syracuse, NYC-based clinical-stage, biopharmaceutical company, raised USD9.79M in Series B funding.
Participating in the financing round were New York Ventures and Consolidated Capital Investments, LLC, and private investors.
The company intends to use the funds to support the progression of its R&D efforts of additional oncological pipeline assets as well as ancillary osteologic treatments. The Series B financing will support the advancement of its lead pipeline asset ZetaMet™ which is currently in Phase 2a clinical trials for the treatment of metastatic breast cancer bone lesions as part of advanced stage cancer therapy. In addition to ZetaMet™, the funding will be used for the development of ZetaMAST™ for the treatment of metastatic lesions to soft tissue organs, as well as other oncologic and osteologic pipeline assets. The company will also add new talent to support these advancing programs.
Led by Joe C. Loy, CEO, Zetagen Therapeutics is a clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic cancers to bone and other organs as well as osteologic interventions. The company was recently issued IP directly associated with the development of ZetaMAST™, which is a formulation designed for intra-tumoral injection in soft tissue organs like the liver, lung and or brain. Its pipeline encompasses further oncological solutions, targeting metastatic prostate cancer and addressing Skeletal Related Events (SREs), such as Z-Pros™ and ZetaMet Flowable™, alongside supplementary treatments for osteological conditions like ZetaFuse™ and ZetaBase®.
FinSMEs
11/08/2023